Research Papers:

LncRNA XIST acts as a tumor suppressor in prostate cancer through sponging miR-23a to modulate RKIP expression

Yang Du, Xiao-Dong Weng, Lei Wang, Xiu-Heng Liu _, Heng-Cheng Zhu, Jia Guo, Jin-Zhuo Ning and Cheng-Cheng Xiao

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:94358-94370. https://doi.org/10.18632/oncotarget.21719

Metrics: PDF 1531 views  |   HTML 2495 views  |   ?  


Yang Du1,*, Xiao-Dong Weng1,*, Lei Wang1,*, Xiu-Heng Liu1, Heng-Cheng Zhu1, Jia Guo1, Jin-Zhuo Ning1 and Cheng-Cheng Xiao1

1Department of Urology, Ren’min Hospital of Wuhan University, Wuhan, Hubei 430000, China

*These authors have contributed equally to this work

Correspondence to:

Xiu-Heng Liu, email: [email protected]

Heng-Cheng Zhu, email: [email protected]

Keywords: prostate cancer, long non-coding RNA, XIST, miR-23a, RKIP

Received: June 29, 2017    Accepted: August 27, 2017    Published: October 10, 2017


Accumulating evidences have indicated that aberrant expression of long non-coding RNAs (LncRNAs) is tightly associated with cancer development. Previous studies have reported that lncRNA XIST regulates tumor malignancies in several cancers. However, the underlying mechanism of XIST in prostate cancer remains unclear. In the current study, we found that XIST was down-regulated in prostate cancer specimens and cell lines. Low expression of XIST was correlated with poor prognosis and advanced tumor stage in prostate cancer patients. In gain and loss of function assays, we confirmed that XIST suppressed cellular proliferation and metastasis in prostate cancer both in vitro and in vivo. Furthermore, we found that XIST negatively regulates the expression of miR-23a and subsequently promotes RKIP expression at post-transcriptional level. Consequently, we investigated the correlation between XIST and miR-23a, and identified miR-23a as a direct target of XIST. In addition, over-expression of miR-23a efficiently abrogated the up-regulation of RKIP induced by XIST, suggesting that XIST positively regulates the expression of RKIP by competitively binding to miR-23a. Taken together, our study indicated that lncRNA XIST acts as a tumor suppressor in prostate cancer, and this regulatory effect of XIST will shed new light on epigenetic diagnostics and therapeutics in prostate cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21719